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Abstract
Potential relationship of vitamin D, vitamin D receptor (VDR), and vitamin D binding protein (DBP) have been suggested in the
pathophysiology of hepatitis C virus (HCV) infection. The aim of this observational study is to determine vitamin D levels, and VDR and
DBP genetic polymorphism according demographic and laboratory data in chronic HCV patients (CHC).
A total of 148 CHC patients gave serum samples for testing 25-hydroxyvitamin D (25 (OH)D) level by immunochemiluminometric
assay (<20ng/mL defined as deficient) and donated blood samples to allelic discrimination analysis using TaqMan assays. Analyzed
single nucleotide polymorphisms (SNPs) were: VDR-rs7975232 (ApaI) C>A, rs731236 A>G (TaqI), rs1544410 C>T (BsmI),
rs10735810 T>C (FokI) and carrier globulin/binding protein (GC)-rs4588 and rs7041 and the haplotype bAt [CCA]. Hepatic fibrosis
was assessed using Fib-4 and Forns index.
Eighty-two (54.40%) patients demonstrated deficiency of vitamin D and this was associated to AST (P= .019 [CI: 1.003–1.034]),
total cholesterol (P= .038 [CI: 1.004–1.164]), fibrosis grade (P< .001 [CI: 0.000–0.844]), and FokI (P= .028) allele T presence.
Association was found between VDR polymorphism and fibrosis (BsmI andTaqI), triglycerides (TaqI), and HDL (FokI). DBP
polymorphism was associated to HCV genotype (GC rs7041), previous HCV treatment, and GGT (GC rs4588).
In conclusion, low frequency of vitamin D deficiencywas found, but VDR polymorphismswere frequently associated to fibrosis grade
suggesting that they could be used as disease evaluationmarkers to understand themechanisms underlying the virus–host interaction.
Abbreviations: ALT = alanine aminotransferase, CHC = chronic hepatitis C, GC = carrier globulin/binding protein, GGT =
gamma-glutamyltransferase, HCV = hepatitis C virus, HDL = high-density lipoprotein, LDL = low-density lipoprotein, 25 (OH)D = 25-
hydroxyvitamin D, RBV = ribavirin, SNP = single nucleotide polymorphism, SVR = sustained virological response, Tc = total
cholesterol, VDR = vitamin D receptor, VLDL = very-low-density lipoprotein.
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11. Introduction
Hepatitis C virus (HCV) is a major cause of chronic hepatitis
responsible for more >185 million worldwide accounting a
seroprevalence of 2.8%.[1–3] Although the incidence rate of HCV
infection is decreasing in the developed countries, deaths from
liver disease secondary to HCV infection will continue to increase
over the next 20 years.[4]
In low- and middle-income countries, interferon and ribavirin
(RBV)-based therapies are the first choices due to their
availability and low cost. The combination of RBV and
pegylated-interferon-alpha was considered the standard treat-
ment for HCV infection in the last decade where those infected
by genotypes 1 and 4 are treated for 48 weeks, and those infected
by genotypes 2 and 3 are treated for 24weeks.[5] Recently, the use
of direct-acting antivirals has proven effective against HCV in
developed countries, significantly decreasing morbidity and
mortality. However, low- and middle-income countries, most
of which are highly endemic areas, access to new antiviral drugs
still is restricted due to high cost.[6]
Several predictors of successful treatment of chronic hepatitis C
(CHC) using interferon and RBV have been identified,[7,8] such as
factors related to the virus (infection byHCV genotype 2–3, basal
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(liver inflammation, fibrosis, lower serum cholesterol values
and interleukin 28B polymorphisms C/C, and vitamin D
concentration).[9–11]
Calcitriol is an important modulator in the immune pathways
and is also known to be involved in cell proliferation and
differentiation.[12] Most of its biological effects are mediated
through the vitamin D receptor (VDR), a member of the
nuclear receptor superfamily of ligand-activated transcription
factors[13–15] and directed to these cells connected with a binding
protein. Carrier globulin/binding protein (GC)-globulin is the
main serum vitamin D binding protein; it is polymorphic and
characterized in Caucasian populations by a great variability at
2 loci (rs7041 and rs4588).[16]
The presence of the minor alleles in GC-globulin loci has been
associated with lower circulating vitamin D levels,[17] instead
VDR polymorphisms has been associated with rapid fibrosis
progression (haplotype bAt[CCA]).[18] Vitamin D deficiency has
been associated to low sustained virological response (SVR)
among hepatitis C patients.[19,20] Moreover, vitamin D levels and
single nucleotide polymorphisms (SNPs) involved in its metabo-
lism have been related to anti-HCV therapy response.[21–23] In
this way, our aim is to evaluate the influence of genetic
determinants of 25-hydroxyvitamin D (25 (OH)D) serum levels
and the association with demographic, metabolic, and virological
data in chronic HCV patients living in South America.2. Methods
2.1. Study design and population
This is an observational study that included 148 CHC patients
resident in Rio de Janeiro recruited at Viral Hepatitis Ambulatory
(Viral Hepatitis Laboratory, Oswaldo Cruz Institute, FIOC-
RUZ), Hepatology Unit (Clementino Fraga Filho University
Hospital, UFRJ), General Medicine Department (Gaffrée Guinle
University Hospital, UNIRIO), and Hepatology Unit (Antonio
Pedro University Hospital, UFF). Nonprobabilistic recruitment
was conducted from 2011 to 2012 year.
Patients were included if they had a virological diagnosis of
CHC (anti-HCV and HCV-RNA reactive serum sample, with
persistently abnormal alanine aminotransferase [ALT], at least 6
months) and more than 18 years of age. The infecting HCV
genotypes were the following: 1, 2, 3, and 5. Patients were
excluded if they were positive for serum hepatitis B surface
antigen or antihuman immunodeficiency virus antibody, or
exhibited other causes of hepatocellular injury (eg, any history of
alcoholism, autoimmune hepatitis, advanced cirrhosis, or
treatment with hepatotoxic drugs), and concomitant use of
drugs known to affect serum vitamin D concentration and
intravenous drug use. These factors were excluded due to
potential source of bias.
This study was approved by the Ethics Committee of
FIOCRUZ (CAAE 41269015.3.0000.5248). Informed consent
was obtained from each patient who was included in the study,
and the study protocol was followed according to the ethical
guidelines of the 1975 Declaration of Helsinki.2.2. Clinical and laboratorial data
All serum samples were tested for anti-HCV using commercial
EIA kit HCV Ab (Radim, Pomezia, Italy), where all anti-HCV-
reactive samples were retested in duplicate.2HCV RNA viral load was determined using CobasTaqMan
HCV Test (Roche Molecular Systems, Inc, Basel, Switzerland) or
Abbott Real Time HCV m2000sp (Abbott Laboratories, IL) and
expressed as IU/mL. HCV genotyping was performed using
INNO-LIPA HCV II kit (Innogenetics, Zwijnaarden, Belgium) or
Abbott Real Time HCV m2000sp (Abbott Laboratories)
according to manufacturer’s instruction.
Clinical and demographic data were collected simultaneously
from all patients. A 12-hour overnight fasting blood sample was
draw to determine serum levels of ALT, gamma-glutamyltrans-
ferase (GGT), total cholesterol (Tc), high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol, triglycer-
ides, plasma glucose concentration, and platelet count.
Baseline serum vitamin D level was assessed by measuring
serum 25 (OH)D levels using automated immunochemilumino-
metric assay (ICMA) (Liason 25 (OH) Vitamin D, Diasorin,
Varceli, Italy) with 20ng/mL being considered the threshold
value. Serum insulin was also determined using ICMA (Liason
Insulin Assay, Diasorin, Varceli, Italy). Insulin resistance was
determined using homeostasis model assessment method
(HOMA ≥2).[24]
Hepatic fibrosis was assessed using Fib-4 and Forns index as
the same as described previously.[25] When Fib-4 was less than
1.45, individual was considered as low fibrosis, and if Fib-4 was
≥1.45, Forns index was considered. Forns index below 4.2 was
considered as low fibrosis, and index above or equal to 4.2 was
considered high fibrosis.[25]
Genomic DNA was obtained from whole blood samples using
QIampDNAMini Kit (Quiagen, Valencia, CA). The purified and
elute DNA was quantified using a Nanodrop Spectrophotometer
ND-1000 (Thermo Scientific, Rockford, IL). Thereafter, DNA
was diluted in UltraPure DNase/RNase-Free water (Invitrogen
Corporation, Camarillo, CA) to a concentration of 2ng. The
allelic discrimination analysis was performed using the TaqMan
assays (Applied Biosystems, Foster City, CA) at ViiA7 Real-Time
PCR System 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA). TaqMan Master mix (2.5mL),
TaqMan assay (0.25mL), and H2O (1.25mL) were added to a
final volume of 4mL per sample, and 1mL of DNA was added for
a total reaction volume of 5mL. Reaction conditions for SNPs
ApaI, FokI, TaqI, and rs4588 were: 10minutes at 95 °C after 50
cycles of denaturation at 95 °C (15seconds) and annealing at 60 °
C (1minute). To genotyping SNPs BsmI and rs7041 TaqMan
Master mix (5.0mL), TaqMan assay (0.50mL), and H2O (3.5mL)
were added to a final volume of 9mL per sample, and 1mLof
DNA was added for a total reaction volume of 10mL. Reaction
conditions for these polymorphisms were: 10minutes at 95 °C
after 50 cycles of denaturation at 95 °C (15seconds) and
annealing at 60 °C (1minute) to BsmI and 61 °C (1minute) to
rs7041.[26]
We selected tag-SNPs from vitamin D metabolism-related
genes, VDR and GC, and the haplotype bAt [CCA]. These SNPs
were chosen using previous literature information.[18,19,26–28]
Public databases were used to collect additional information
about SNPs and genes: NCBI http://www.ncbi.nlm.nih.gov.
The analyzed SNPs were: VDR-rs7975232 (ApaI) C>A,
rs731236 A>G (TaqI), rs1544410 C>T (BsmI), rs10735810
T>C (FokI) and GC-rs4588 and rs7041. According to Pubmed
Database, the frequencies were: GC (rs7041): A=0.4841/58741
(ExAC) C=0.3816/1911 (1000 Genomes); GC (rs4588): T=
0.2528/30670 (ExAC) T=0.2079/1041 (1000 Genomes);
BsmI rs1544410: T=0.2959/1482 (1000 Genomes); ApaI
(rs7975232): C=0.4813/58108 (ExAC) C=0.4846/2427
Table 1
Demographic, laboratory, and metabolic data of 148 chronic
hepatitis patients (CHC).
Variable Value
Age, y 54.41 (±11.27)
Gender
Female 92 (62.2%)
Male 56 (37.8%)
25 (OH)D, ng/mL 23.08 (±10.48)
HCV RNA, IU/mL 571,000,000 (12–3,060,000,000)
Log 5.75 (1.08–7.48)
Glucose, ng/mL 107.66 (±47.28)
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G=0.2766/1385 (1000 Genomes); and FokI (rs10735810): A=
0.3285/1645.
Haplotypes were constructed from the combination of the
VDR polymorphisms BsmI, ApaI, and TaqI {bAt [CCA] [“b”
(BsmI allele C), “A” (ApaI allele C), and “t” (TaqI allele A)]} and
their frequencies were inferred using the PHASE 2.1.1 program
(Matthew Stephens Lab, University of Chicago). To predict both
allele frequencies will remain constant because they are in
equilibrium, we calculated the Hardy–Weinberg equilibrium by
X2 (P< .05).AST, UI/mL 76.00 (4–397)
ALT UI/mL 69.00 (±58.33)
VLDL, mg/dL 19.82 (±10.83)
LDL, mg/dL 151.96 (±190.94)
HDL, mg/dL 54.80 (±20.86)
Triglycerides, mg/dL 102.52 (±45.90)
Total cholesterol, mg/dL 233.75 (±197.55)
gGT, UI/mL 124.62 (±121.55)
Insulin, mU/mL 18.60 (±24.56)
HOMA 1.99 (±3.33)
APRI 1.61 (±2.25)
FORNS 3.42 (±7.01)
Fib-4 3.84 (±4.46)
TSH 3.34 (±7.77)
Hemoglobin, ng/mL 13.64 (±1.78)
Hematocrit, % 40.64 (6.48)
Phosphatase, UI/mL 111.32 (±85.54)
Platelets, 103/mm 20,479.70492 (±60,563.37)
Antiviral treatment
Without SVR 46 (31.08%)
With SVR 22 (14.86%)
No treatment 68 (45.94%)2.3. Statistical analysis
Continuous data are expressed as mean± standard deviation, and
the categorical data are expressed as number (percentage).
Comparisons of differences in categorical date between groups
were performed using the Chi-square test. Distributions of
continuous variables were analyzed by the Student t test or
Mann–Whitney U test for the 2 groups where appropriate.
Missing data were presented in tables when appropriate.
Independent factors possibly affecting 25 (OH)D concentration
(cut off value of 20ng/mL) were determined by stepwise multiple
logistic regression analysis.
Hardy–Weinberg equilibrium for each SNP was compared
using the Pearson chi-square test (X2). 25 (OH)D concentration
and the variance in each genotype was accessed in one-way
ANOVA with Bonferroni correction. At univariate analyses, P-
value were considered significant when PY<Y.2 and in
multivariate analyze PY<Y.05. All the tests were performed
with IBM SPSS Statistics 20.0 for Windows (Chicago, IL).Genotype
∗
1 114 (88.37%)
None-1 15 (11.62%)
25 (OH)D
<20 82 (55.40%)
≥20 66 (44.60%)
HOMA
<2 49 (33.10%)
≥2 99 (66.90%)
Fibrosis algorithm
∗
Low 41 (27.70%)
High 77 (52.00%)
Continuous variables are expressed as mean value± standard deviation. ALT= alanine
aminotransferase, AST= aspartate aminotransferase, CHC=chronic hepatitis C, gGT=gamma
glutamyltransferase, HCV=hepatitis C virus, HDL=high-density lipoprotein, HOMA=homeostatic
model assessments, LDL= low-density lipoprotein, 25 (OH)D = 25-hydroxyvitamin D, SVR=
sustained virological response, VLDL= very-low-density lipoprotein.
∗
With missing data.3. Results
3.1. Baseline characteristics
Demographic, virological, and clinical features of population
studied are shown in Table 1. There were 56 men and 92 women,
with mean age of 54.41 (±11.27). Elevated mean of ALT, AST,
phosphatase, GGT, blood glucose, Tc, and LDL serum levels
were observed in patients.
Normal median values were observed for: very-low-density
lipoprotein (VLDL) cholesterol (19.82±10.83mg/dL), HDL
(54.80±20.86mg/dL), platelets (20,479.70492±60,563.37103/
mm), hematocrit (40.64%±6.48%), and hemoglobin (13.64±
1.78ng/mL) (anemic classification: hemoglobin values<12ng/mL
for women and <13ng/mL for men). Using the cutoff value of 20
ng/mL, 82/148 (54.40%) patients demonstrated deficiency of
vitamin D. HCV RNA viral load (log mean) was high and most
prevalent genotype was 1 (88.37%). During this study, 68
CHC patients were treated for HCV using pegylated-interferon
and RBV and in this subgroup, 46 (31.08%) did not achieve SVR.
Sixty-eight patients (45.94%) were not treated for HCV. Using
fibrosis algorithm, 52.00% (n=77) presented high level. The
HOMA index mean was also lower than the cutoff established in
this work (1.99±3.33), where 33.10% (n=49) presented insulin
resistance.3.2. Association between serum 25 (OH)D levels, clinical
and viral data in chronic HCV patients
To assess the relationship among 25 (OH)D concentration and
demographic and laboratory data in HCV patients, a cutoff value3was established (deficiency<20ng/mL). High mean values of age
(P= .042), AST (P= .022), HDL (P= .072), triglycerides (0.047),
SVR (P= .108), and presence of high fibrosis (P= .016) were
associated to 25 (OH)D deficiency at univariate analysis.
Patients with high rates of platelets presented 25 (OH)D ≥20
ng/mL (P= .014), as also blood glucose (P= .106) and ALT
(P= .160) were high in patients with 25 (OH)D ≥20ng/mL
(Table 2). At multiple linear regression analysis, AST (P= .019
[CI: 1.003–1.034]), Tc (P= .038 [CI: 1.004–1.164]), and fibrosis
grade (P< .001 [CI: 0.000–0.844]) were significant.
Table 2
Univariate and multivariate regression analysis of factors associated with 25 (OH) concentration.
Variable <20 25 (OH)D, ng/mL ≥20 Bivariate analysis P value Multivariate analysis P (CI)
Age, y 57 (±9) 52 (±12) .042 .967 (0.943–1.063)
Gender
Female, n 47 (%) 45 (%) .041 .882 (0.254–4.937)
Male, n 19 (%) 37 (%)
Log HCV RNA, UI/mL 5.38 (±1.60) 5.082 (±1.84) .572 
Glucose, ng/mL 105.89 (±45.06) 109.26 (±49.51) .106 0.102 (0.992–1.093)
AST, UI/mL 100.45 (±67.45) 79.73 (±42.97) .022 .019 (1.003–1.034)
ALT, UI/mL 59.80 (±49.30) 77.09 (±64.18) .160 .109 (0.853–1.016)
VLDL, mg/dL 21.74 (±10.32) 17.83 (±11.08) .205 
LDL, mg/dL 162.42 (±199.99) 141.51 (±182.62) .357 
HDL, mg/dL 57.48 (±20.71) 52.01 (±20.84) .072 .075 (0.983–1.429)
Tg, mg/dL 108.71 (±51.80) 96.10 (±86) .344 
Tc, mg/dL 251.21 (±207.63) 215.62 (±186.76) .047 .038 (1.004–1,164)
gGT, UI/mL 131.21 (±141.62) 119.18 (±102.70 .824 
TSH 4.75 (±10.85) 2.0 (±1.640) .040 .110 (0.669–52.71)
Hemoglobin, ng/mL 13.59 (±1.37) 13.69 (±2.08) .422 
Hematocrit, % 40.54 (5.16) 40.79 (7.48) .232 
Phosphatase, UI/mL 116.57 (±96.27) 106.98 (±75.90) .532 
Platelets, 103/mm 5162.316 (±21730.170) 33911.87 (±78289.79) .014 .087 (0.932–1.005)
Response to antiviral treatment (n=68)
∗
.108 .5 (0.035–969.661)
SVR, n 5 17
Without SVR, n 21 25
Genotype (n=129)
∗
1 46 68 .341 
None-1 8 7
HOMA
<2 46 53 .517 
≥2 20 29
Fibrosis algorithm (n=118)
∗
Low 13 28 .016 .000 (0.000–0.844)
High 43 34
Continuous variables are expressed as mean value± standard deviation. ALT= alanine aminotransferase, AST= aspartate aminotransferase, CI= confidence interval, gGT=gamma glutamyltransferase, HCV=
hepatitis C virus, HDL=high-density lipoprotein, HOMA=homeostatic model assessments, LDL= low-density lipoprotein, SVR= sustained virological response, Tc= total cholesterol, Tg= triglycerides, VLDL=
very-low-density lipoprotein.
∗
With missing data.
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according to 25 (OH)D level among HCV patients
To study the implication of these SNPs and 25 (OH)D
concentration according to clinical and laboratory data
of HCV patients, first our sample was categorized
according to previously defined cutoff value (25 (OH)D
deficiency<20ng/mL). Second, the alleles were categorized in
risk allele/nonrisk allele and grouped, and presence/absence of
haplotype bAt [CCA]. The genotype distribution of all
investigated SNPs was in Hardy–Weinberg equilibrium. Only
FokI was statistically significant (P= .028), where allele T were
associated with 25 (OH)D ≥20ng/mL.
After this, the one-way ANOVA test with Bonferroni multiple
comparison posttest (P< .05) was done. There was no statisti-
cally difference between SNPs genotypes and 25 (OH)D
concentration in 148 Brazilian CHC patients (Fig. 1). ApaI:
(CC vs CA [t=0.172], CC vs AA [t=0.199], CA vs AA [t=
0.430]); TaqI: (AA vs AG [t=0.806], AA vs GG [t=0.990], AG
vs GG [t=0.497]); BsmI: (CC vs CT [t=1.281], CC vs TT [t=
0.564], CT vs TT [t=0.278]); FokI: (CC vs CT [t=1.786], CC vs
TT [t=0.961], CT vs TT [t=2.040]); GC rs4588: (AA vs AC [t=
0.927], AA vs CC [t=0.101], AC vs CC [t=1.515]); GC rs7041:
(TT vs TG [t=0.610], TT vs GG [t=2.001], TG vs GG [t=
1.565]).4Besides that we carried out a bivariate and a linear regression
analysis by comparing favorable allele group with demographic,
biochemical, and viral data. The significant results are given in
Table 3. In the multivariate analysis, using SPNs as dependent
variable, we found association between BsmIrs1544410 (fibrosis
algorithm), TaqI rs731236 (triglycerides and fibrosis algorithm),
FokI rs10735810 (HDL), GC rs4588 (treated and none-treated,
and GGT), and GC rs7041 (genotype 1 and none-1).
4. Discussion
In vitamin D pathway, a series of studies had reported on
interaction between vitamin D-related genes and 25 (OH)D levels.
Among them, VDR and vitamin D-binding protein (DBP) genes
played an important role in vitamin D pathway. Previous studies
had shown that genetic variations in these genes had a significant
effect on vitamin D levels in many populations including the
Chinese,[29,30] Japanese,[31] Caucasian,[16,17,19,20,27] Brazilian
healthy girls,[26] and in this study, FokI C allele in Brazilian
CHC patients were associated to 25 (OH)D <20ng/mL.
This way, we hypothesized that genetic determinants of 25
(OH)D serum levels may be associated with demographic,
metabolic, and virological data in chronic HCV Brazilian
patients. To our knowledge, this is the first study that describes
the interaction between vitamin D-related genes and 25 (OH)D
Figure 1. Association of VDR and GC gene polymorphism with 25 (OH)D concentration in Brazilian chronic HCV patients. No significant variance was found using
ANOVA I test with Bonferroni correction (P< .05). GC=carrier globulin/binding protein, HCV=hepatitis C virus, 25 (OH)D=25-hydroxyvitamin D, VDR=vitamin D
receptor.
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some new insight about these parameters in tropical regions.
In this study, the prevalence of vitamin D deficiency was
55.04% that is lower than previously observed in similar
population in Brazil (63%)[25] and among Italians HCV patients
(73%).[20,22,23,32] Moreover, severe fibrosis was found in patients
with lower vitamin D concentration (Table 2). Lange et al[19] also
found that the prevalence of vitamin D deficiency was greater in
HCV patients with more advanced fibrosis.
In the present study, Fib-4 and Forns index were used to
determine fibrosis level since they are useful for predicting fibrosis
grade in the absence of biopsy.[33,34] Forns index can be used to
differentiate patients with mild (F0–F1) fibrosis from those with
severe (F2–F4) fibrosis demonstrating diagnostic performance of
AUROC 0.76 to 0.79 for the detection of significant fibrosis. FIB-
4 index correctly identified patients with severe fibrosis (F3–F4)
and cirrhosis with an AUROC of 0.85 and 0.91, respectively. An
FIB-4 index <1.45 had a negative predictive value of 94.7% to
exclude severe fibrosis and a sensitivity of 74.3%. An FIB-4 index
higher than 3.25 had a positive predictive value of 82.1% for the
confirmation of significant fibrosis (F3–F4), with a specificity of
98.2%.[35,36]5Vitamin D deficiency is common among patients with liver
diseases.Whether vitamin D status can also affect liver function is
poorly understood. In this study, low 25 (OH)D concentration
was associated with high AST and cholesterol total value. Skaaby
et al[37] investigate the association between vitamin D status, liver
enzymes, and incident liver disease in 2649 individuals and found
that the risk of having a high level of ALT, AST, or GGT tended
to be higher for lower vitamin D levels, in accordance with our
results.
There is conflicting information when it comes to the link
between cholesterol and vitamin D levels. Population studies
show that people with lower vitamin D levels are more likely to
have high cholesterol, although this does not prove a cause and
effect relationship despite being according our findings.[38] To the
National Institutes of Health, there is insufficient evidence to
determine any relationship between vitamin D intake and
cholesterol levels.
It was not found an association between vitamin D levels and
HCV RNA mean values. Conversely, Gerova et al[39] found an
inverse relationship between 25 (OH)D and HCV-RNA levels in
Bulgarian HCV patients. These differences could be due to
variation in the 25 (OH)D assay used, vitamin D cutoff, and the
Table 3
Univariate and multivariate regression analysis of factors asso-
ciated with VDR-ApaI rs7975232, TaqI rs731236, BsmI rs1544410,
FokIrs10735810, GC-rs4588, and GC-rs7041 SNPs.
SNP
Bivariate
analysis P value
Multivariate
analysis P (CI)
BsmI rs1544410
Total cholesterol, mg/dL .080 .524 (0.998–1.003)
HOMA .019 .987 (0.887–1.125)
Fibrosis algorithm .030 .040 (0.048–0.554)
Genotype 1/none-1 .148 .360 (0.240–2.444)
TaqI rs731236
Total cholesterol, mg/dL .045 .116 (0.999–1.005)
Triglycerides, mg/dL .194 .033 (0.978–0.999)
AST, UI/mL .184 .452 (0.994–1.013)
Hematocrit, % .114 .456 (0.868–1.065)
Fibrosis algorithm .164 .019 (1.320–21.746)
ApaI rs7975232
HOMA .018 .027 (0.171–0.900)
Age .138 .087 (0.917–1.006)
Gender .153 .125 (0.838–4,247)
FokI rs10735810
LDL, mg/dL .035 .106 (0.998–1.018)
HDL, mg/dL .106 .012 (0.889–0.995)
gGT, mg/dL .115 .133 (0.979–1.003)
Insulin, mU/mL .163 .871 (0.926–1.067)
SVR/without SVR .019 .097 (0.728–44.221)
GC rs4588
Treated/untreated .023 .679 (0.070–59.088)
AST, UI/mL .082 .244 (0.989–1.047)
Total cholesterol, mg/dL .057 .159 (0.995–1.029)
gGT, mg/dL .014 .057 (0.999–1.056)
Platelets, 103/mm .059 .044 (1.000–1.034)
GC rs7041
Fibrosis algorithm .191 .620 (0.213–2.514)
Genotype 1/NON-1 .001 .011 (0.023–0.608)
AST, UI/mL .155 .757 (0.987–1.018)
ALT, UI/mL .109 .784 (0.988–1.016)
VLDL, mg/dL .127 .454 (0.874–1.351)
LDL, mg/dL .115 .676 (0.997–1.002)
HDL, mg/dL .163 .763 (0.972–1.021)
Triglycerides, mg/dL .188 .658 (0.947–1.035)
gGT, mg/dL .084 .236 (0.998–1.010)
Univariate analysis: P< .2; multivariate analysis P< .05. Only statistical significant variables in
bivariate analysis were demonstrated and included in multiple logistic regression analysis to better
present the data. ALT= alanine aminotransferase, AST= aspartate aminotransferase, CI= confidence
interval, GC=carrier globulin/binding protein, gGT=gamma glutamyltransferase, HDL=high-density
lipoprotein, HOMA=homeostatic model assessments, LDL= low-density lipoprotein, SVR= sustained
virological response, VDR= vitamin D receptor, VLDL= very-low-density lipoprotein.
Scalioni et al. Medicine (2018) 97:8 Medicinedifferent ethnicities and geographic latitude of populations
studied, and clinical trials.
A strong association of vitamin D sufficiency to TT genotype in
FokI was found. This way, FokI C>T polymorphisms may be
used as a molecular marker to predict the risk and to evaluate the
disease severity of HCC in those infected with HCV since low
concentrations of vitamin D is directly associated with increased
liver injury in Brazilian population. Differently, Shehab et al[40]
observed that VDR genetic polymorphisms are significantly
associated with the occurrence of HCV-related HCC especially T
allele carriers which could be considered as a risk factor of
hepatocellular carcinoma in Egyptian patients.
Regarding VDR and DBP genes polymorphisms in Brazilian
population, the BsmI, ApaI, TaqI, and the rs4588 and rs70416polymorphisms were most consistently associated with lower 25
(OH)D levels.[26,40] However, in the present study both SNPs
were not associated with lower levels of 25 (OH)D after applying
Bonferroni correction. Nevertheless, Falleti et al[16] demonstrated
that normal serum vitamin D levels and the carriage of GC-
globulin WT isoform strongly predict the achievement of SVR
after PEG-interferon plus RBV antiviral therapy. Some studies
found that the carriage of ApaI CC genotype and TaqI AA
genotype had significant higher viral load as compared to those
with ApaI CA/AA type and TaqI AG type, respectively.[28]
Besides that, VDR gene variants can modulate biological effects
of vitamin D without influencing serum vitamin D levels.[15,41]
Some variables could explain these differences. It is well
established that there are racial differences in the relations
between the 25 (OH)D concentrations, parathyroid hormone
concentration, and calcium homeostasis.[14] Racial differences in
vitamin D physiology or race-specific factors that modify the
effects of vitamin D may affect the immune response to HCV.[42]
We did not find a significant association between VDR bAt
[CCA] haplotype and clinical and laboratory data in HCV
patients as the same as Hung et al[28] who also did not find any
relationship between this haplotype and response to peginter-
feron plus RBV therapy. These genetic variations have been
described as important modulators of several chronic liver
diseases such as primary biliary cirrhosis and autoimmune
hepatitis.[43]
In the present study, fibrosis was associated to BsmI rs1544410
and TaqI rs731236 what was not observed among Chinese
population with chronic HCV infection.[28] To explain the
relation between high serum triglycerides and the effect of TaqI
rs731236, a hypothetical explanation is related to the mechanism
in which vitamin D induces the expression of VLDL-cholesterol
receptors in some types of cell.[44] This situation is associatedwith
an elevation of the levels of VLDL and triglycerides and is
common in CHC patients.[45] The relationship between HCV
genotype and GC remains unknown.
This study presents some limitations, like the absence of race
information or ancestry profile, sun exposure, and season of
collection that could create some bias regarding vitamin D
measures.
In conclusion, the present study suggests a significant
association of VDR FokI rs10735810 and the 25 (OH)D
concentration in CHC patients, strong association between
fibrosis algorithm, 25 (OH)D, BsmI rs15444, and TaqI
rs731236, and finally the association between GC rs7041
(Genotype 1/ None-1). These data could provide helpful
information for understanding the complex mechanisms under-
lying the virus–host interaction and the variations observed in
antiviral therapy responses.Acknowledgment
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